Director's share purchase
29 October, 2015 - C4X Discovery Holdings plc (C4XD), a leader in rational drug discovery and design, announces that Clive Dix, Chairman of C4XD, purchased 50,000 ordinary shares of 1 pence each ("Ordinary Shares") on 28 October 2015 at a price of 67.5p per Ordinary Share.
Following this transaction, Clive has an interest in 641,250 Ordinary Shares, representing approximately 2.07 per cent of the Company's issued ordinary share capital.
--ENDS--
For further information please contact:
C4X Discovery Holdings plc
Piers Morgan, CEO 07912 293832
Zeus Capital
Dan Bate / Jonathan Sharp 0161 831 1512
Dominic Wilson 020 3829 5000
FTI Consulting
Matthew Cole / Brett Pollard / Rob Winder / Matthew Moss 020 3727 1000
About C4XD
C4XD (AIM: C4XD) is a Manchester-based company focused on optimising drug discovery and design. It was founded in 2008 as a spin-out from the University of Manchester. The company uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since C4XD's NMR technology shows what shapes active molecules prefer to adopt, it provides high-quality templates for rational drug discovery and design, and valuable conformational information for drug candidate optimisation. In addition, the data is generated faster and more reliably than standard techniques such as X-ray co-crystallography or molecular modelling. C4XD is using its technology in collaboration with the pharmaceutical industry and to build its own proprietary pipeline of high-value therapeutic candidates. For additional information please go to: www.c4xdiscovery.com